Zenotech Laboratories

Zenotech Laboratories CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is 81.55 %. In the previous year, CapEx to Operating Cash Flow Ratio was 40.71 % — a change of 100.30% (higher).

CapEx/OCF

81.55 %

YoY

100.30%

Last updated:

CapEx to Operating Cash Flow Ratio of Zenotech Laboratories is 2026 81.55 % . CapEx to Operating Cash Flow Ratio of Zenotech Laboratories was 2025 40.71 % . It decreases by 100.30% higher compared to the previous year.

The Zenotech Laboratories CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
-128.41 INR
Jan 1, 2020
191.11 INR
Jan 1, 2021
85.55 INR
Jan 1, 2022
10.97 INR
Jan 1, 2023
30.16 INR
Jan 1, 2024
35.81 INR
Jan 1, 2025
40.71 INR
Jan 1, 2026
81.55 INR
The Zenotech Laboratories CapEx/OCF history
YEARCapEx/OCFYoY
81.55 %+100.30%
40.71 %+13.70%
35.81 %+18.74%
30.16 %+174.99%
10.97 %-87.18%
85.55 %-55.23%
191.11 %-248.82%
-128.41 %+445.66%
-23.53 %-154.43%
43.24 %-34,687.23%
-0.13 %-80.47%
-0.64 %-89.10%
-5.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

CapEx to Operating Cash Flow Ratio of Zenotech Laboratories is 81.55 % in 2026.

CapEx to Operating Cash Flow Ratio of Zenotech Laboratories changed from 40.71 % to 81.55 %, representing a 100.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories